دورية أكاديمية
أعرض في EDS

A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

التفاصيل البيبلوغرافية
العنوان: A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.
المؤلفون: Lage DP; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Ribeiro PAF; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Dias DS; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Mendonça DVC; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Ramos FF; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Carvalho LM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais Brazil., de Oliveira D; Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, 88806-000 Santa Catarina Brazil., Steiner BT; Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, 88806-000 Santa Catarina Brazil., Martins VT; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Perin L; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Machado AS; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Santos TTO; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Tavares GSV; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Oliveira-da-Silva JA; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Oliveira JS; Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Roatt BM; Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Departamento de Ciências Biológicas, Insituto de Ciências Exatas e Biológicas, Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais Brazil., Machado-de-Ávila RA; Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma, 88806-000 Santa Catarina Brazil., Teixeira AL; Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX USA., Humbert MV; Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, SO16 6YD UK., Coelho EAF; Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais Brazil., Christodoulides M; Neisseria Research Group, Molecular Microbiology, School of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, SO16 6YD UK.
المصدر: NPJ vaccines [NPJ Vaccines] 2020 Aug 13; Vol. 5, pp. 75. Date of Electronic Publication: 2020 Aug 13 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Nature in partnership with the Sealy Center for Vaccine Development Country of Publication: England NLM ID: 101699863 Publication Model: eCollection Cited Medium: Internet ISSN: 2059-0105 (Electronic) Linking ISSN: 20590105 NLM ISO Abbreviation: NPJ Vaccines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Springer Nature in partnership with the Sealy Center for Vaccine Development, [2016]-
مستخلص: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are currently no prophylactic vaccines. In this study, we designed in silico a synthetic recombinant vaccine against visceral leishmaniasis (VL) called ChimeraT, which contains specific T-cell epitopes from Leishmania Prohibitin, Eukaryotic Initiation Factor 5a and the hypothetical LiHyp1 and LiHyp2 proteins. Subcutaneous delivery of ChimeraT plus saponin stimulated a Th1 cell-mediated immune response and protected mice against L. infantum infection, significantly reducing the parasite load in distinct organs. ChimeraT/saponin vaccine stimulated significantly higher levels of IFN-γ, IL-12, and GM-CSF cytokines by both murine CD4 + and CD8 + T cells, with correspondingly low levels of IL-4 and IL-10. Induced antibodies were predominantly IgG2a isotype and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide. ChimeraT also induced lymphoproliferative responses in peripheral blood mononuclear cells from VL patients after treatment and healthy subjects, as well as higher IFN-γ and lower IL-10 secretion into cell supernatants. Thus, ChimeraT associated with a Th1 adjuvant could be considered as a potential vaccine candidate to protect against human disease.
Competing Interests: Competing interestsThe authors declare no competing interests.
(© The Author(s) 2020.)
References: Front Cell Infect Microbiol. 2017 May 31;7:200. (PMID: 28620584)
Sci Rep. 2017 Aug 15;7(1):8285. (PMID: 28811600)
PLoS Negl Trop Dis. 2013;7(3):e2148. (PMID: 23573301)
Emerg Microbes Infect. 2019;8(1):1178-1185. (PMID: 31381478)
PLoS One. 2012;7(5):e35671. (PMID: 22693548)
Trends Parasitol. 2015 Dec;31(12):653-664. (PMID: 26440786)
PLoS Negl Trop Dis. 2012 Jan;6(1):e1430. (PMID: 22272364)
Front Immunol. 2014 Aug 22;5:380. (PMID: 25202307)
PLoS One. 2014 Sep 30;9(9):e108556. (PMID: 25268700)
Mol Immunol. 2019 Feb;106:108-118. (PMID: 30594673)
J Immunol Methods. 2015 Jul;422:1-12. (PMID: 25858230)
Vaccine. 2019 Jun 12;37(27):3505-3519. (PMID: 31103364)
Mol Immunol. 2017 Nov;91:272-281. (PMID: 28988041)
Int J Prev Med. 2019 Jun 07;10:95. (PMID: 31360342)
Front Immunol. 2019 Feb 28;10:288. (PMID: 30873164)
Parasite Immunol. 2015 Dec;37(12):646-56. (PMID: 26457798)
Cytokine. 2020 Feb 12;129:155031. (PMID: 32062145)
Parasit Vectors. 2017 Dec 21;10(1):617. (PMID: 29268793)
Braz J Infect Dis. 2001 Aug;5(4):223-32. (PMID: 11712967)
PLoS Negl Trop Dis. 2016 Mar 10;10(3):e0004468. (PMID: 26962865)
J Clin Invest. 1995 Mar;95(3):1183-92. (PMID: 7883967)
Anal Biochem. 1976 May 7;72:248-54. (PMID: 942051)
Methods Mol Biol. 2007;409:185-200. (PMID: 18450001)
Ther Adv Infect Dis. 2016 Jun;3(3-4):98-109. (PMID: 27536354)
Vaccine. 2018 Apr 19;36(17):2293-2299. (PMID: 29573875)
Front Cell Infect Microbiol. 2018 Nov 13;8:381. (PMID: 30483480)
Clin Vaccine Immunol. 2015 Nov;22(11):1187-96. (PMID: 26376929)
Anal Biochem. 1982 Oct;126(1):131-8. (PMID: 7181105)
Transl Res. 2018 Oct;200:18-34. (PMID: 29908151)
EMBO J. 2000 Jun 1;19(11):2444-51. (PMID: 10835343)
Front Microbiol. 2016 Mar 22;7:312. (PMID: 27047452)
Clin Microbiol Rev. 1993 Jul;6(3):230-50. (PMID: 8358705)
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3825-30. (PMID: 18308940)
Expert Opin Drug Deliv. 2010 Dec;7(12):1343-58. (PMID: 21029028)
Parasit Vectors. 2016 Mar 01;9:118. (PMID: 26932389)
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8. (PMID: 12824418)
Parasite Immunol. 2017 Jan;39(1):. (PMID: 27593711)
Indian J Med Res. 2013 Apr;137(4):767-76. (PMID: 23703346)
Acta Trop. 2016 Feb;154:73-81. (PMID: 26593442)
Biochem Biophys Res Commun. 2003 Dec 12;312(2):459-66. (PMID: 14637159)
PLoS Negl Trop Dis. 2016 Jan 11;10(1):e0004322. (PMID: 26752686)
Nucleic Acids Res. 2017 Jul 3;45(W1):W24-W29. (PMID: 28472356)
Parasitology. 2019 Sep;146(11):1467-1476. (PMID: 31142384)
PLoS Negl Trop Dis. 2014 Oct 02;8(10):e3198. (PMID: 25275531)
Mol Immunol. 2016 Aug;76:70-9. (PMID: 27387277)
Microb Pathog. 2019 Nov;136:103704. (PMID: 31479726)
Microbes Infect. 2017 Jun;19(6):358-369. (PMID: 28373107)
Immunology. 2018 Jul;154(3):394-406. (PMID: 29315598)
Expert Opin Pharmacother. 2013 Jan;14(1):53-63. (PMID: 23256501)
Front Immunol. 2018 Apr 23;9:843. (PMID: 29740446)
Immunobiology. 2018 Mar;223(3):303-309. (PMID: 29074301)
Parasit Vectors. 2016 May 12;9(1):277. (PMID: 27175732)
Cell Microbiol. 2010 Apr 1;12(4):432-52. (PMID: 19888987)
Scand J Immunol. 2017 Jul;86(1):15-22. (PMID: 28426153)
Infect Immun. 2003 Nov;71(11):6499-509. (PMID: 14573672)
Front Immunol. 2014 May 23;5:241. (PMID: 24904589)
Biol Signals. 1997 May-Jun;6(3):105-9. (PMID: 9285092)
J Biomol Struct Dyn. 2019 Jun;37(9):2381-2393. (PMID: 30047323)
Front Cell Infect Microbiol. 2018 Apr 05;8:112. (PMID: 29675401)
Vaccine. 2002 Jan 31;20(9-10):1365-8. (PMID: 11818154)
J Immunol. 2018 Jan 1;200(1):163-176. (PMID: 29187586)
Lancet. 2018 Sep 15;392(10151):951-970. (PMID: 30126638)
Diagn Microbiol Infect Dis. 2018 Nov;92(3):196-203. (PMID: 29941364)
Int J Mol Sci. 2019 Apr 12;20(8):. (PMID: 31013713)
Cytokine. 2018 Nov;111:131-139. (PMID: 30142534)
Microbes Infect. 2010 Nov;12(12-13):967-77. (PMID: 20601076)
Cell Immunol. 2017 Mar;313:32-42. (PMID: 28049560)
J Immunol. 2002 Dec 1;169(11):6580-7. (PMID: 12444170)
FEBS Lett. 1990 Dec 10;276(1-2):172-4. (PMID: 1702393)
Immunogenetics. 2010 Jun;62(6):357-68. (PMID: 20379710)
Cell Immunol. 2018 Jan;323:59-69. (PMID: 29128045)
معلومات مُعتمدة: MR/R005850/1 United Kingdom MRC_ Medical Research Council
فهرسة مساهمة: Keywords: Diseases; Infectious diseases; Microbiology; Parasitic infection; Vaccines
تواريخ الأحداث: Date Created: 20200822 Latest Revision: 20210715
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7426426
DOI: 10.1038/s41541-020-00224-0
PMID: 32821440
قاعدة البيانات: MEDLINE
الوصف
تدمد:2059-0105
DOI:10.1038/s41541-020-00224-0